Line 1: |
Line 1: |
− | test
| + | __TOC__ |
| + | |
| + | == Contributors == |
| + | |
| + | Write your comments here |
| + | |
| + | == Tumor Type == |
| + | |
| + | Write your comments here <ref>Test Reference: Nowell and Hungerford (1962). Chromosome studies in human leukemia. IV. Myeloproliferative syndrome and other atypical myeloid disorders. ''J Natl Cancer Inst'' 29:911-31 PMID:[http://www.ncbi.nlm.nih.gov/pubmed/?term=13939164 13939164] </ref> |
| + | |
| + | == Tumor Classification == |
| + | |
| + | Write your comments here |
| + | |
| + | == Description == |
| + | |
| + | Write your comments here |
| + | |
| + | == IHC Markers == |
| + | |
| + | Write your comments here |
| + | |
| + | == Genomic Gain/Loss/LOH == |
| + | |
| + | Write your comments here |
| + | |
| + | == Rearrangements == |
| + | |
| + | Write your comments here |
| + | |
| + | == Mutations (SNV/INDEL) == |
| + | |
| + | Write your comments here |
| + | |
| + | === From Cosmic Mutated in >20% === |
| + | === Mutated in 10-20% === |
| + | === Mutated in 5-10% === |
| + | === Mutated in 2-5% === |
| + | === mtDNA === |
| + | |
| + | == Epigenomics (methylation) == |
| + | |
| + | Write your comments here |
| + | |
| + | == Main Pathways Involved == |
| + | |
| + | Write your comments here |
| + | |
| + | == Clinical Significance == |
| + | |
| + | Write your comments here |
| + | |
| + | == Diagnosis == |
| + | |
| + | Write your comments here |
| + | |
| + | == Prognosis == |
| + | |
| + | Write your comments here |
| + | |
| + | == Therapeutics == |
| + | |
| + | Write your comments here |
| + | |
| + | == Familial Forms == |
| + | |
| + | Write your comments here |
| + | |
| + | ==References== |
| + | {{Reflist}} |